[{"address1": "Bahnhofstrasse 20", "city": "Zug", "zip": "6300", "country": "Switzerland", "phone": "41 41 711 3960", "website": "https://oculis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Dr. Riad  Sherif M.B.A., M.D.", "age": 57, "title": "CEO & Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sylvia  Cheung", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gudrun  Bachmann Ph.D.", "title": "Chief Technology Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramin  Tadayoni M.D., Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel S. Char J.D.", "age": 64, "title": "Chief Legal Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Virginia R. Dean", "age": 59, "title": "Chief Human Resources Officer", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. P\u00e1ll Ragnar J\u00f3hannesson", "age": 43, "title": "Chief Business Officer", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rebecca  Weil Ph.D.", "title": "Chief Commercial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Snehal  Shah Pharm.D.", "title": "President of Research & Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Klier M.D., M.P.H.", "title": "Chief Development Officer", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 23.84, "open": 23.82, "dayLow": 23.69, "dayHigh": 26.17, "regularMarketPreviousClose": 23.84, "regularMarketOpen": 23.82, "regularMarketDayLow": 23.69, "regularMarketDayHigh": 26.17, "payoutRatio": 0.0, "beta": 0.135, "forwardPE": -11.113266, "volume": 428162, "regularMarketVolume": 428162, "averageVolume": 133135, "averageVolume10days": 266740, "averageDailyVolume10Day": 266740, "bid": 25.11, "ask": 25.32, "bidSize": 1, "askSize": 1, "marketCap": 1457890176, "fiftyTwoWeekLow": 14.0, "fiftyTwoWeekHigh": 26.17, "allTimeHigh": 26.17, "allTimeLow": 6.26, "priceToSalesTrailing12Months": 1843.0975, "fiftyDayAverage": 20.3366, "twoHundredDayAverage": 18.900475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1178178688, "profitMargins": 0.0, "floatShares": 39923747, "sharesOutstanding": 57806909, "sharesShort": 316332, "sharesShortPriorMonth": 49197, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0055, "heldPercentInsiders": 0.027520001, "heldPercentInstitutions": 0.40775, "shortRatio": 2.96, "shortPercentOfFloat": 0.0063, "impliedSharesOutstanding": 57806909, "bookValue": 3.1024387, "priceToBook": 8.129088, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -104098000, "trailingEps": -2.69, "forwardEps": -2.2693598, "enterpriseToRevenue": 1489.48, "enterpriseToEbitda": -15.146, "52WeekChange": 0.11395764, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 25.22, "targetHighPrice": 54.985035, "targetLowPrice": 28.848555, "targetMeanPrice": 44.28805, "targetMedianPrice": 45.215195, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 145180000, "totalCashPerShare": 2.772, "ebitda": -77789000, "totalDebt": 2466000, "quickRatio": 4.373, "currentRatio": 4.474, "totalRevenue": 791000, "debtToEquity": 1.888, "revenuePerShare": 0.016, "returnOnAssets": -0.33353, "returnOnEquity": -0.92195, "grossProfits": -54769000, "freeCashflow": -29590624, "operatingCashflow": -58847000, "revenueGrowth": 0.125, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -83.52263, "financialCurrency": "CHF", "symbol": "OCS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1768603105, "regularMarketTime": 1768597200, "exchange": "NGM", "messageBoardId": "finmb_589165623", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 5.78859, "regularMarketPrice": 25.22, "shortName": "Oculis Holding AG", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1621344600000, "postMarketChangePercent": 0.11895594, "postMarketPrice": 25.25, "postMarketChange": 0.030000687, "regularMarketChange": 1.38, "regularMarketDayRange": "23.69 - 26.17", "epsTrailingTwelveMonths": -2.69, "epsForward": -2.2693598, "epsCurrentYear": -1.80573, "priceEpsCurrentYear": -13.96665, "fiftyDayAverageChange": 4.8834, "fiftyDayAverageChangePercent": 0.24012864, "twoHundredDayAverageChange": 6.319525, "twoHundredDayAverageChangePercent": 0.334358, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-03-03", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "longName": "Oculis Holding AG", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 133135, "fiftyTwoWeekLowChange": 11.219999, "fiftyTwoWeekLowChangePercent": 0.8014285, "fiftyTwoWeekRange": "14.0 - 26.17", "fiftyTwoWeekHighChange": -0.95000076, "fiftyTwoWeekHighChangePercent": -0.036301136, "fiftyTwoWeekChangePercent": 11.395764, "earningsTimestamp": 1772571600, "earningsTimestampStart": 1772571600, "earningsTimestampEnd": 1772571600, "isEarningsDateEstimate": false, "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]